サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363362

オピオイドの市場規模、シェア、動向分析レポート：製品別、用途別、投与経路別、流通チャネル別、地域別、セグメント予測、2023年～2030年

Opioid Market Size, Share & Trends Analysis Report By Product (IR/ Short Acting Opioids, ER/Long-Acting Opioids), Application (Pain Relief, Anesthesia), Route Of Administration, Distribution Channel, Region, & Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オピオイドの市場規模、シェア、動向分析レポート：製品別、用途別、投与経路別、流通チャネル別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月28日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オピオイド市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のオピオイド市場規模は2030年までに253億米ドルに達し、予測期間中のCAGRは1.4％を記録する見込みです。

支持的な規制政策は、市場成長に貢献する可能性のある製品を導入するメーカーを支援しています。例えば、2021年6月に米国FDAは、Purdue Pharma L.P.が開発した塩酸ナルメフェン注射剤を承認しました。ナルメフェン注射剤は、オピオイドの過剰摂取を逆転させるように設計されたオピオイド拮抗薬です。この製品の承認は、成長を促進すると予想されています。

さらに、2021年6月には、硫酸モルヒネ錠剤と硫酸モルヒネ内服液が、他の治療選択肢が少ない小児および成人患者の重度の疼痛管理用としてFDAから承認されました。このように、新たなオピオイドの承認とその発売も成長を促進すると予想されます。

手術による術後疼痛の管理にオピオイドが使用されるケースが増加していることも、市場成長の原動力になると予想されます。Canadian Centre on Substance Use and Addictionによると、2020年には全人口の約11.8%が症状管理のためにオピオイド鎮痛薬を使用しています。同地域では、手術後のオピオイド処方として、トラマドールやコデインが頻繁に調剤されています。

疼痛管理のためにオピオイドに代わる非中毒性の製品が登場したことで、オピオイド市場の成長は低下しています。American Society of Anesthesiologists（米国麻酔科学会）によると、市販のステロイドやアスピリン、イブプロフェン、アセトアミノフェンなどの非ステロイド性抗炎症薬など、オピオイド以外の医薬品がいくつかあります。さらに、これらの薬に関連する幅広い入手可能性と低コストは、予測期間中にそのような製品の需要の増加に寄与しています。例えば、アスピリンは30錠入りで10米ドルです。

さらに、米国FDAは2022年2月、急性および慢性疼痛の管理に関するHHS過剰摂取防止戦略の下、オピオイドに代わる非中毒性鎮痛薬の開発を奨励するイニシアティブを開始しました。FDAは製薬会社に対し、非オピオイド鎮痛薬の開発を推奨しています。こうした取り組みは、オピオイド市場全体の成長を抑制する可能性があります。

オピオイド市場レポートハイライト

  • 製品別では、新規ER/長時間作用型オピオイドの承認・上市の増加により、ER/長時間作用型オピオイド分野が2022年に最大の市場シェアを占めました。例えば、2021年6月、米国FDAは疼痛管理用ブプレノルフィン（Brixadi）の新薬承認申請を受理しました。ブプレノルフィンは徐放性長時間作用型オピオイド薬です。
  • 用途別では、疼痛緩和分野が2022年のオピオイド市場を席巻し、慢性疼痛患者の増加により大幅な市場成長が見込まれています。2021年のカナダ健康情報研究所とカナダ疼痛タスクフォースの報告書によると、カナダでは成人の5人に1人が慢性疼痛に苦しんでいます。
  • 投与経路別では、注射剤が2022年のオピオイド市場を独占しました。この優位性は、慢性疼痛の治療に使用される製品が広く入手可能であることと、麻酔を必要とする処置が増加していることに起因しています。
  • 流通チャネル別では、小売薬局が2022年のオピオイド市場を独占しました。オピオイドの調剤率が高い小売薬局が存在することが、同分野の成長を牽引しています。
  • 予測期間中、アジア太平洋地域が最も急成長する見込みです。同地域の成長は、慢性疼痛に罹患しやすい老年人口の増加に起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オピオイド市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • オピオイド市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 オピオイド：製品別推定・動向分析

  • オピオイド市場：重要なポイント
  • オピオイド市場：動向と市場シェア分析、2022年と2030年
  • IR/短時間作用型オピオイド
  • ER/長時間作用型オピオイド

第5章 オピオイド：用途別推定・動向分析

  • オピオイド市場：重要なポイント
  • オピオイド市場：動向と市場シェア分析、2022年および2030年
  • 鎮痛剤
  • 麻酔
  • 咳止め
  • 下痢の抑制
  • 脱依存症

第6章 オピオイド：投与経路別推定・動向分析

  • オピオイド市場：重要なポイント
  • オピオイド市場：動向と市場シェア分析、2022年および2030年
  • 経口
  • 注射
  • その他

第7章 オピオイド：流通チャネル別推定・動向分析

  • オピオイド市場：重要なポイント
  • オピオイド市場：動向と市場シェア分析、2022年および2030年
  • 病院薬局
  • 小売薬局
  • その他

第8章 オピオイド市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別のオピオイド市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Purdue Pharma L.P.
    • Johnson & Johnson Services, Inc.
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd
    • Grunenthal
    • Merck & Co., Inc.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America opioids market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America opioids market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 5 North America opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America opioids market, by region, 2018 - 2030 (USD Million)
  • Table 7 U.S. opioids market, by product, 2018 - 2030 (USD Million)
  • Table 8 U.S. opioids market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 10 U.S. opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada opioids market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada opioids market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 14 Canada opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe opioids market, by product, 2018 - 2030 (USD Million)
  • Table 16 Europe opioids market, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 18 Europe opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Europe opioids market, by region, 2018 - 2030 (USD Million)
  • Table 20 Germany opioids market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany opioids market, by application, 2018 - 2030 (USD Million)
  • Table 22 Germany opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 23 Germany opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK opioids market, by product, 2018 - 2030 (USD Million)
  • Table 25 UK opioids market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 27 UK opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France opioids market, by product, 2018 - 2030 (USD Million)
  • Table 29 France opioids market, by application, 2018 - 2030 (USD Million)
  • Table 30 France opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 31 France opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy opioids market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy opioids market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 35 Italy opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain opioids market, by product, 2018 - 2030 (USD Million)
  • Table 37 Spain opioids market, by application, 2018 - 2030 (USD Million)
  • Table 38 Spain opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 39 Spain opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark opioids market, by product, 2018 - 2030 (USD Million)
  • Table 41 Denmark opioids market, by application, 2018 - 2030 (USD Million)
  • Table 42 Denmark opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 43 Denmark opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden opioids market, by product, 2018 - 2030 (USD Million)
  • Table 45 Sweden opioids market, by application, 2018 - 2030 (USD Million)
  • Table 46 Sweden opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 47 Sweden opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway opioids market, by product, 2018 - 2030 (USD Million)
  • Table 49 Norway opioids market, by application, 2018 - 2030 (USD Million)
  • Table 50 Norway opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 51 Norway opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific opioids market, by product, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific opioids market, by application, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 55 Asia Pacific opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific opioids market, by region, 2018 - 2030 (USD Million)
  • Table 57 Japan opioids market, by product, 2018 - 2030 (USD Million)
  • Table 58 Japan opioids market, by application, 2018 - 2030 (USD Million)
  • Table 59 Japan opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 60 Japan opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 China opioids market, by product, 2018 - 2030 (USD Million)
  • Table 62 China opioids market, by application, 2018 - 2030 (USD Million)
  • Table 63 China opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 64 China opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India opioids market, by product, 2018 - 2030 (USD Million)
  • Table 66 India opioids market, by application, 2018 - 2030 (USD Million)
  • Table 67 India opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 68 India opioids market, by distribution channel, (USD Million) 2018 - 2030
  • Table 69 Australia opioids market, by product, 2018 - 2030 (USD Million)
  • Table 70 Australia opioids market, by application, 2018 - 2030 (USD Million)
  • Table 71 Australia opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 72 Australia opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Thailand opioids market, by product, 2018 - 2030 (USD Million)
  • Table 74 Thailand opioids market, by application, 2018 - 2030 (USD Million)
  • Table 75 Thailand opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 76 Thailand opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 South Korea opioids market, by product, 2018 - 2030 (USD Million)
  • Table 78 South Korea opioids market, by application, 2018 - 2030 (USD Million)
  • Table 79 South Korea opioids market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 South Korea opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America opioids market, by product, 2018 - 2030 (USD Million)
  • Table 82 Latin America opioids market, by application, 2018 - 2030 (USD Million)
  • Table 83 Latin America opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 84 Latin America opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 Latin America opioids market, by region, 2018 - 2030 (USD Million)
  • Table 86 Brazil opioids market, by product, 2018 - 2030 (USD Million)
  • Table 87 Brazil opioids market, by application, 2018 - 2030 (USD Million)
  • Table 88 Brazil opioids market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Brazil opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico opioids market, by product, 2018 - 2030 (USD Million)
  • Table 91 Mexico opioids market, by application, 2018 - 2030 (USD Million)
  • Table 92 Mexico opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 93 Mexico opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina opioids market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina opioids market, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 97 Argentina opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 Middle East and Africa opioids market, by product, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa opioids market, by application, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 101 Middle East and Africa opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa opioids market, by region, 2018 - 2030 (USD Million)
  • Table 103 South Africa opioids market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa opioids market, by application, 2018 - 2030 (USD Million)
  • Table 105 South Africa opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 106 South Africa opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia opioids market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia opioids market, by application, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 110 Saudi Arabia opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE opioids market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE opioids market, by application, 2018 - 2030 (USD Million)
  • Table 113 UAE opioids market, by route of administration, (USD Million) 2018 - 2030
  • Table 114 UAE opioids market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait opioids market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait opioids market, by application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait opioids market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait opioids market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Opioids: Market outlook
  • Fig. 9 Opioids: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Opioids market driver impact
  • Fig. 15 Opioids market restraint impact
  • Fig. 16 Opioids market strategic initiatives analysis
  • Fig. 17 Opioids market: Product movement analysis
  • Fig. 18 Opioids market: Product outlook and key takeaways
  • Fig. 19 IR/Short acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 20 ER/Long acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 21 Opioids market: Application movement analysis
  • Fig. 22 Opioids market: Application outlook and key takeaways
  • Fig. 23 Pain relief market estimates and forecasts, 2018 - 2030
  • Fig. 24 Anesthesia market estimates and forecasts, 2018 - 2030
  • Fig. 25 Cough suppression market estimates and forecasts, 2018 - 2030
  • Fig. 26 Diarrhea suppression market estimates and forecasts, 2018 - 2030
  • Fig. 27 De-addiction market estimates and forecasts, 2018 - 2030
  • Fig. 28 Opioids market: Route of administration movement analysis
  • Fig. 29 Opioids market: Route of administration outlook and key takeaways
  • Fig. 30 Oral market estimates and forecasts, 2018 - 2030
  • Fig. 31 Injectable market estimates and forecasts, 2018 - 2030
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030
  • Fig. 33 Opioids market: Distribution channel movement analysis
  • Fig. 34 Opioids market: Distribution channel outlook and key takeaways
  • Fig. 35 Hospital pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Retail pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030
  • Fig. 38 Global opioids market: Regional movement analysis
  • Fig. 39 Global opioids market: Regional outlook and key takeaways
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 46 France market estimates and forecasts, 2018 - 2030
  • Fig. 47 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 48 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 49 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 50 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 51 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 53 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 54 China market estimates and forecasts, 2018 - 2030
  • Fig. 55 India market estimates and forecasts, 2018 - 2030
  • Fig. 56 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 57 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 58 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 59 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 60 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 62 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 64 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 65 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 66 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-2-68038-131-3

Opioids Market Growth & Trends:

The global opioid market size is expected to reach USD 25.3 billion by 2030, registering a CAGR of 1.4% during the forecast period, according to a new report by Grand View Research, Inc.. Supportive regulatory policies aid manufacturers to introduce products that may contribute to the market growth. For instance, in June 2021, the U.S. FDA approved nalmefene hydrochloride injection developed by Purdue Pharma L.P.Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose. The expected approval of a product is anticipated to drive the growth.

Moreover, in June 2021, morphine sulfate tablets and morphine sulfate oral solution were approved by FDA for the management of severe pain in pediatric and adult patients for whom other treatment options were less. Thus, approval of new opioid and their launch is also expected to drive the growth.

Growing use of the opioids for the management of post-operative pain, caused due to the surgeries, is expected to drive the market growth. According to the Canadian Centre on Substance Use and Addiction, in 2020, approximately 11.8% of all the population used opioid analgesics for the management of symptoms. Tramadol and codeine are frequently dispensed for the postoperative opioid prescription in surgeries within the region.

Emergence of non-addictive alternative products to opioids for the pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets.

In addition, in February 2022, the U.S. FDA has undertaken an initiative to encourage the development of non-addictive analgesics alternatives to opioids under its HHS overdose prevention strategy for the management of acute and chronic pain. The regulatory agency issued recommendation to pharmaceutical companies to develop non-opioid analgesic products. Such initiatives may restrain the overall growth of the opioids market.

Opioids Market Report Highlights:

  • By product, ER/long acting opioids segment held the largest market share in 2022 due to the increasing approval and launch of the novel ER/ long-acting opioids. For instance, in June 2021, the U.S. FDA accepted a review application for a new drug application for buprenorphine (Brixadi) for the pain management. Buprenorphine is an extended release long-acting opioid drug
  • By application, pain relief segment dominated the opioids market in 2022 and is expected to witness significant market growth owing to increasing prevalence of the patients with chronic pain. According to the Canadian Institute for Health Information and Canadian Pain Task Force report of 2021, 1 in every 5 adults in Canada suffers from chronic pain
  • By route of administration, injectable segment dominated the opioids market in 2022. This dominance can be attributed to wide availability of products used for the treatment of chronic pain and increased procedures requiring anesthesia
  • By distribution channel, retail pharmacy dominated the opioids market in 2022. The availability of retail pharmacies with high dispensing rate of opioid driving segment growth
  • Asia pacific is expected to be the fastest growing region during the forecast period. The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Route of administration
    • 1.1.4. Distribution channel
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Distribution channel outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Opioids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Opioids Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Opioids: Product Estimates & Trend Analysis

  • 4.1. Opioids Market: Key Takeaways
  • 4.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. IR/Short Acting Opioids
    • 4.3.1. IR/ Short Acting Opioids market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. ER/Long Acting Opioids
    • 4.4.1. ER/ Long Acting Opioids market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Opioids: Application Estimates & Trend Analysis

  • 5.1. Opioids Market: Key Takeaways
  • 5.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Pain Relief
    • 5.3.1. Pain relief market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Anesthesia
    • 5.4.1. Anesthesia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Cough Suppression
    • 5.5.1. Cough suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Diarrhea Suppression
    • 5.6.1. Diarrhea suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. De-addiction
    • 5.7.1. De-addiction market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Opioids: Route of Administration Estimates & Trend Analysis

  • 6.1. Opioids Market: Key Takeaways
  • 6.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Oral
    • 6.3.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Injectable
    • 6.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Opioids: Distribution Channel Estimates & Trend Analysis

  • 7.1. Opioids Market: Key Takeaways
  • 7.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 7.3. Hospital Pharmacy
    • 7.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4. Retail Pharmacy
    • 7.4.1. Retail Pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Opioids Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Outlook
  • 8.2. Opioids Market by Region: Key Takeaways
  • 8.3. North America
    • 8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.3. France
      • 8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.6. Sweden
      • 8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.7. Norway
      • 8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.5.2. China
      • 8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.5.3. India
      • 8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.5.5. Thailand
      • 8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.5.6. South Korea
      • 8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.6.2. Mexico
      • 8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.7. MEA
    • 8.7.1. Saudi Arabia
      • 8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Market Participant Categorization
    • 9.2.1. Purdue Pharma L.P.
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. Johnson & Johnson Services, Inc.
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Hikma Pharmaceuticals PLC
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Pfizer Inc.
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. AbbVie Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Sanofi
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Sun Pharmaceutical Industries Ltd
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Grunenthal
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Merck & Co., Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives